Last reviewed · How we verify
Infuvite Adult (Nicotinamide)
Infuvite Adult (generic name: Nicotinamide) is a Standardized Chemical Allergen [EPC] Small molecule drug developed by Pfizer. It is currently FDA-approved (first approved 1953) for Acne vulgaris, Niacin deficiency, Pellagra. Also known as: Enduramide, Niacin (Vitamin B3), niacinamide, Decitabine.
Infuvite Adult is a multivitamin product that contains dydrogesterone and niacinamide, a form of vitamin B3. It is being studied in clinical trials for various conditions, including fibroids, colorectal cancer, stroke, transient ischemic attack, and gastrointestinal microbiome disorders.
At a glance
| Generic name | Nicotinamide |
|---|---|
| Also known as | Enduramide, Niacin (Vitamin B3), niacinamide, Decitabine, Tetrahydrouridine |
| Sponsor | Pfizer |
| Drug class | Standardized Chemical Allergen [EPC] |
| Target | NAD-dependent protein deacetylase sirtuin-2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Acne vulgaris
- Niacin deficiency
- Pellagra
Common side effects
- Rash
- Erythema
- Pruritis
- Headache
- Dizziness
- Agitation
- Anxiety
- Diplopia
Serious adverse events
- Anaphylaxis
- Anaphylactoid reactions
- Shortness of breath
- Wheezing
- Angioedema
- Allergic reactions to thiamine
- Hypervitaminosis A
Key clinical trials
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (PHASE1)
- Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate (NA)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia (EARLY_PHASE1)
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (PHASE1)
- Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment (PHASE4)
- MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib (PHASE3)
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infuvite Adult CI brief — competitive landscape report
- Infuvite Adult updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Infuvite Adult
What is Infuvite Adult?
What is Infuvite Adult used for?
Who makes Infuvite Adult?
What is the generic name of Infuvite Adult?
Is Infuvite Adult also known as anything else?
What drug class is Infuvite Adult in?
When was Infuvite Adult approved?
What development phase is Infuvite Adult in?
What are the side effects of Infuvite Adult?
What does Infuvite Adult target?
Related
- Drug class: All Standardized Chemical Allergen [EPC] drugs
- Target: All drugs targeting NAD-dependent protein deacetylase sirtuin-2
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Acne vulgaris
- Indication: Drugs for Niacin deficiency
- Indication: Drugs for Pellagra
- Also known as: Enduramide, Niacin (Vitamin B3), niacinamide, Decitabine, Tetrahydrouridine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing